Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation

Authors
Blackshear, JL Zabalgoitia, M Pennock, G Fenster, P Strauss, R Halperin, J Asinger, R Pearce, LA
Citation
Jl. Blackshear et al., Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation, AM J CARD, 83(3), 1999, pp. 453
Citations number
10
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
AMERICAN JOURNAL OF CARDIOLOGY
ISSN journal
00029149 → ACNP
Volume
83
Issue
3
Year of publication
1999
Database
ISI
SICI code
0002-9149(19990201)83:3<453:WSAEIP>2.0.ZU;2-V
Abstract
Patients with atrial fibrillation and with documented aortic plaque who wer e assigned to adjusted-dose warfarin therapy (international normalized rati o 2.0 to 3.0) had an annual rate of cholesterol embolization of 0.7% (95% c onfidence interval [CI] 0.1% to 5.3%/patient-year). Warfarin-assigned patie nts with plaque had a lower rate of embolic events (5.9%/year; 95% CI 3.0 t o 12) than those on combination low-dose warfarin (international normalized ratio <1.5) plus aspirin (17.3%/year; 95% CI 11 to 27; p = 0.01).